Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.

Today Kedrion Biopharma announced the nationwide commercial availability of QIVIGY, its FDA‑approved 10% Intravenous ...

SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.

In 1996, a previously healthy 5-year-old girl presented to a local urgent care clinic with a 3-day history of fever and a progressive, generalized vesicular rash, diagnosed as varicella with a known ...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year GrowthFY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% ...

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

Adjusted EBITDA -- $231 million, up 40% year over year, demonstrating significant operating leverage. Adjusted net income -- $160.8 million, a 35% year-over-year increase, confirming margin expansion ...

Q4 2025 Earnings Call February 25, 2026 4:30 PM ESTCompany ParticipantsAdam Grossman - Co-Founder, President, CEO ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...

Checkpoint inhibitors may work best when they are given early in the day, suggests clinical data from a phase III trial in patients with non-small-cell lung cancer (NSCLC). Patients who received a PD1 ...